Literature DB >> 28625652

Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.

Maria Gion1, Jordi Remon2, Caroline Caramella3, Jean-Charles Soria4, Benjamin Besse5.   

Abstract

Leptomeningeal metastasis (LM) is reported in 3.8% of non-small-cell lung cancer (NSCLC) patients, more frequently in adenocarcinoma, and it correlates with poor prognosis. Data regarding the activity of immune checkpoint inhibitors in LM is lacking. We present a case report about the efficacy of nivolumab in a patient with advanced NSCLC and symptomatic LM.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lung cancer; Meningeal carcinomatosis; Nivolumab

Mesh：

Substances：

Year:  2017        PMID： 28625652     DOI： 10.1016/j.lungcan.2017.02.022

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  10 in total

1.  The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review.

Authors:  Paolo Palmisciano; Ali S Haider; Chibueze D Nwagwu; Waseem Wahood; Kenny Yu; Chibawanye I Ene; Barbara J O'Brien; Salah G Aoun; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh
Journal:  Anticancer Res       Date:  2021-11       Impact factor: 2.435

2.  Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis.

Authors:  Suneel D Kamath; Priya U Kumthekar; Tim J Kruser; Nisha A Mohindra
Journal:  Oncologist       Date:  2018-08-02

3.  Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report.

Authors:  Yunmei Wang; Shuguang Liu; Xiaohui Wei; Bin Yan; Jun Li; Zhixiang Su; Aiqin Liu; Yanjun Zhang
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

Review 4.  Leptomeningeal disease: current diagnostic and therapeutic strategies.

Authors:  Gautam Nayar; Tiffany Ejikeme; Pakawat Chongsathidkiet; Aladine A Elsamadicy; Kimberly L Blackwell; Jeffrey M Clarke; Shivanand P Lad; Peter E Fecci
Journal:  Oncotarget       Date:  2017-08-16

5.  Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series.

Authors:  Huiying Li; Tingting Yu; Mingmin Huang; Aibin Guo; Xiaoping Qian; Zhenyu Yin
Journal:  Onco Targets Ther       Date:  2019-09-20       Impact factor: 4.147

Review 6.  Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.

Authors:  Simon Nannini; Larysa Koshenkova; Seyyid Baloglu; Dominique Chaussemy; Georges Noël; Roland Schott
Journal:  J Neurooncol       Date:  2022-04-13       Impact factor: 4.506

Review 7.  [Advances in Diagnosis and Treatment of Leptomeningeal Metastasis of Lung Cancer].

Authors:  Naisheng Gao; Tao Xin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-07-20

8.  Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.

Authors:  Junjie Zhen; Lei Wen; Mingyao Lai; Zhaoming Zhou; Changguo Shan; Shaoqun Li; Tao Lin; Jie Wu; Wensheng Wang; Shaoqiang Xu; Da Liu; Ming Lu; Dan Zhu; Longhua Chen; Linbo Cai; Cheng Zhou
Journal:  Radiat Oncol       Date:  2020-07-31       Impact factor: 3.481

9.  [Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer].

Authors:  Zhiqin Lu; Jing Cai; Zhimin Zeng; Anwen Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-06

10.  Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.

Authors:  Zhi-Qin Lu; Jing Cai; Xia Wang; Jian-Ping Wei; Zhi-Min Zeng; Long Huang; An-Wen Liu
Journal:  Thorac Cancer       Date:  2020-11-17       Impact factor: 3.223
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.